The endothelial protein C receptor (EPCR) plays an important role in cardiovascular disease by binding protein C/activated protein C (APC). EPCR structure contains a hydrophobic groove filled with an unknown phospholipid needed to perform its function. It is unknown whether lipid exchange takes place in EPCR as a regulatory mechanism of its activity. Our objective was to identify this phospholipid and to explore the possibility of a lipid exchange as a regulatory mechanism of EPCR activity driven by the endothelially expressed secretory group V phospholipase A2 (sPLA2-V). We identified phosphatidylcholine (PCh) as the major phospholipid bound to human soluble EPCR (sEPCR). PCh in EPCR could be exchanged by lysophosphatidylcholine (lysoPCh) and platelet activating factor (PAF). Remarkably, lysoPCh and PAF impaired the protein C binding ability of sEPCR. Inhibition of sPLA2-V, responsible for lysoPCh and PAF generation, improved APC binding to endothelial cells. Accordingly, EPCR-dependent protein C activation and APC antiapoptotic effect were significantly enhanced. Endothelial cell supplementation with sPLA2-V resulted in the opposite effects. In summary, EPCR accommodates PCh within its hydrophobic groove.
INTRODUCTION
The endothelial cell protein C/activated protein C receptor (EPCR) is a transmembrane glycoprotein that is abundantly expressed on the surface of the endothelium of the large vessels. 1 EPCR binds protein C, activated protein C (APC), and factor VII/VIIa (FVII/VIIa) with high affinity. 2, 3 Upon EPCR binding on the endothelial surface, protein C activation by the thrombin-thrombomodulin complex is notably increased and factor Xa-dependent FVII activation is reduced. 4, 5 EPCR is a cornerstone molecule in the protein C system which plays an important role in cardiovascular pathologies such as thrombosis, coronary artery disease and stroke, [6] [7] [8] and is involved in mechanisms of vascular biology such as inflammation and endothelial barrier protection related to sepsis, lung function and metastasis. 9, 10 Previous structural studies showed that EPCR folds into two alpha chains which, together with a β-sheet platform, conform a hydrophobic groove. This is occupied by a phospholipid which has not yet been identified but which is necessary to preserve the ligand binding properties of EPCR. 11 One of the aims of the present work was to identify the exact nature of this phospholipid. Since EPCR shares significant homology with CD1d and MHC-class I like molecules which behave as lipid antigen-presenting molecules, 12 we speculated that the EPCR hydrophobic pocket could be filled with more than one phospholipid. We provide evidence that fully active EPCR accommodates phosphatidylcholine (PCh) within its hydrophobic groove and that, interestingly, secretory group V phospholipase A2 (sPLA2-V)
generates bioactive lipids i.e. lysophosphatidylcholine (lysoPCh) and platelet activating factor (PAF) in the vicinity of EPCR which, by displacing phosphatidylcholine from the hydrophobic groove, notably impair the ability of EPCR to interact with protein C and FVII.
MATERIALS AND METHODS
An expanded version is available in the Supplemental Methods section.
Recombinant proteins expression and purification
Human and murine yeast-derived sEPCR as well as human mammalian cell-derived sEPCR were expressed and purified as described.
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Lipid extraction from sEPCR variants and subsequent lipid identification
The lipid fraction of sEPCR was extracted for subsequent analysis by thin layer chromatography (TLC) and mass spectrometry analysis.
Lipid extraction for subsequent analysis of sEPCR function
n-octyl-β-d-Glucopyranoside was used to extract the lipid from the yeast-derived sEPCR.
The delipidated sEPCR was subsequently used for surface plasmon resonance (SPR) and fluorescence spectroscopy analyses as explained below.
Assessment of the interaction between lipids and sEPCR by fluorescence spectroscopy analysis
The binding of PCh, lysoPCh, PAF and S1P to human delipidated sEPCR was studied by measuring the changes in the intrinsic fluorescence of delipidated sEPCR upon incubation with increasing amounts of the lipids. The data were used to calculate the dissociation constant (K D ) for each lipid.
Assessment of the interaction between lysoPCh or PAF and sEPCR by mass spectrometry
Each lipid was incubated with sEPCR at 10-fold excess. Once the unbound lipid was removed by gel exclusion chromatography, the lipid fraction of the eluted protein was extracted and analyzed by mass spectrometry.
Biomolecular interaction analyses by SPR
All interaction experiments were performed by SPR technology using a BIAcore X Biosensor (GE Healthcare) basically as previously described.
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Flow cytometry experiments
All the flow cytometry experiments were performed in a FACScalibur (BD Biosciences). The binding of APC to endothelial cells was performed as described. 3 The expression of EPCR, thrombomodulin and sPLA2-V on the surface of cells was assessed using anti-human EPCR RCR-2, anti-human thrombomodulin and anti-human sPLA2-V monoclonal antibodies (mAbs) respectively. Apoptosis of staurosporine-stimulated endothelial cells was assessed by incubating them with fluorescently-labeled annexin V and actinomicine D.
Activation of protein C on the endothelial surface
The effect of manoalide and sPLA 2 -V on APC generation by thrombin on the surface of HAEC or EA.hy926 was studied as previously described.
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Immunohistochemical assessment of sPLA2-V expression in tissues
Sections from carotid arteries from mice subjected to a laser injury-induced thrombosis 16 and from human left atrial appendages were analyzed for the presence of sPLA2-V using an antisPLA2-V Ab followed by the anti-rabbit Dako Envision+ System-HRP, and for the presence of fibrin deposits using Masson's Trichrome staining.
RESULTS
PCh is the phospholipid located in the hydrophobic pocket of EPCR
The lipid fraction extracted from yeast-expressed human sEPCR migrated in the TLC plate as a single spot exactly as PCh standard did. The same result was obtained using human sEPCR produced in mammalian cells, thus suggesting that the lipid naturally occupying the pocket of human sEPCR is PCh ( Figure 1A) . The experiment performed with murine sEPCR revealed a major spot corresponding to PCh and a minor one which migrates like PE.
To further analyze the nature of the EPCR lipid content, the sEPCR organic extract was subjected to mass spectrometry analysis which showed a peak at m/z 786, whose fragmentation yielded a pattern of peaks that are characteristic of the PCh polar group ( Figure   1B 
PCh is essential for EPCR to interact with its ligands
We used SPR technology to analyze whether PCh was necessary to preserve the ability of sEPCR to interact with APC. The affinity of EPCR for APC was around 10-times lower when PCh was removed from sEPCR (K D = 64 ± 8 and 616 ± 156 nM with and without PCh respectively, n = 3) (Figure 2A , 2B), a result that is coherent with previous findings. 11 The ability of APC to bind to delipidated sEPCR was fully recovered after incubation with PCh ( Figure 2C ). Of note, the K D was 62 ± 27 nM (n = 3), very similar to the obtained with non-manipulated sEPCR. Delipidated sEPCR also lost the ability to bind to FVIIa (K D = 83 ± 16
and 625 ± 147 nM with and without PCh respectively).
LysoPCh and PAF but not S1P can locate in the hydrophobic pocket of EPCR
Since lysoPCh is derived from PCh and preserves the structure of the latter except that it lacks one of the fatty acid groups (Supplemental Figure 1) , we speculated that EPCR could accommodate it. For this reason we used fluorescence spectroscopy to monitor whether the intrinsic fluorescence of delipidated sEPCR changed upon incubation with lysoPCh. As can be seen, the three lysoPCh forms tested did modify the intrinsic fluorescence in a dosedependent manner ( Figure 3A) . As a reference, changes in the intrinsic fluorescence of To gain further evidence regarding the interaction between sEPCR and lysoPCh or PAF we incubated delipidated sEPCR with lysoPCh (a mixture of 16:0 and 18:0) or PAF, removed the excess of lipid by gel exclusion chromatography and extracted the lipid fraction bound to the purified protein to subject it to mass spectrometry analysis. Peaks were obtained at both m/z 496 and 524 in the case of LysoPCh, which correspond to the MW of the lysoPCh molecules used in the experiment. Furthermore, the fragmentation spectrum was identical to that obtained with pure lysoPCh 16:0 or 18:0. These results confirm that lysoPCh does bind to EPCR (Supplemental Figure 2 ). In the case of PAF, we detected a peak at m/z 524, which corresponds to the molecular weight of PAF, and the fragmentation spectrum was identical to that obtained with pure PAF (Supplemental Figure 3 ).
LysoPCh and PAF displace PCh from the EPCR pocket and impair APC binding
The finding that these "one-armed" phospholipids bind to EPCR prompted us to determine whether the presence of this lipid could alter EPCR interaction with APC. We incubated delipidated sEPCR with lysoPCh and observed that, unlike PCh, lysoPCh did not restore the ability of delipidated sEPCR to bind to APC ( Figure 3B ). Finding out whether lysoPCh was able to displace PCh from the EPCR hydrophobic groove thus became a particularly appealing aim. For this reason we incubated sEPCR (note that in this case sEPCR still retains its natural phospholipid) with a 100 molar excess of lysoPCh 16:0, 18:0 or 18:1. Then we captured this sEPCR with RCR-2 mAb immobilized on a SPR sensor chip surface in order to check its ability to bind to APC. The binding was again notably reduced ( Figure 3C ), which not only provides further evidence that lysoPCh abrogates the EPCR ligand interaction properties but interestingly means that lysoPCh is able to actively displace the original lipid from the hydrophobic pocket.
We also examined the effect of PAF on the sEPCR ability to bind to APC. We demonstrated that the APC binding ability of delipidated sEPCR was not recovered upon PAF reconstitution. The same result i.e. reduced binding, was observed when sEPCR was preincubated with 100 molar excess PAF and subsequently tested with immobilized APC ( Figure 3D ).
The binding of APC to EPCR on endothelial cells is modulated by the action of sPLA 2 -V
It was worthwhile at this point to examine whether lysoPCh and PAF were also able to bind to EPCR on the cell surface and thus decrease its APC binding efficiency. Figure 5A , 5B). Interestingly, we also detected positive sPLA 2 -V staining in a human thrombus formed in the left atrium of a patient with atrial fibrillation as well as on the endocardial surface nearby ( Figure 5F , 5G), whereas we detected no staining in the left atrial endocardium of a donor free of cardiac abnormalities ( Figure 5E ).
DISCUSSION
EPCR improves the efficiency of protein C activation and is involved in cell signaling mechanisms resulting in antiapoptotic, antiinflammatory and endothelial barrier protective effects. 4, 9 When the crystal structure of EPCR was solved, a phospholipid inside its hydrophobic groove was found. However, the nature of this phospholipid remained yet to be elucidated. 11 We provide enough evidence to claim that the major lipid located within the hydrophobic pocket of EPCR is PCh. Of note and according to previous studies, 11 its removal caused a remarkable decrease in APC affinity, which was restored upon PCh supplementation. A similar finding was obtained with FVIIa, thus confirming the important role played by the phospholipid in ligand binding. 3 Our results are consistent with those obtained with the highly homologous CD1d, which is also loaded with PCh in its hydrophobic groove. Furthermore, a recent "in silico" simulation suggested a relationship between the phospholipid binding to EPCR and the size of the surface of interaction with protein C, which would be reduced i.e. ligand binding would be worsened, in the absence of the phospholipid. 21 The key role played by PCh in EPCR function led us to speculate that its substitution by another lipid could influence its ligand binding ability. Lipid exchange occurs in CD1d and was anticipated for EPCR in the "in silico" study. 21 Among bioactive lipids, lysoPCh exhibits a high structural homology with PCh, since it is the product of an enzymatic process that removes one of the fatty acids from the latter. Furthermore, lysoPCh binds to CD1d. 17, 22 For these reasons we studied whether EPCR was able to bind to lysoPCh. Among the lysoPCh variants, we choose the most abundant ones in human physiology. 23 When incubated with delipidated EPCR, lysoPCh dose-dependently modified its intrinsic fluorescence.
Furthermore, the mass spectrometry pattern of the lipid fraction extracted from the reconstituted EPCR fully corresponded to lysoPCh. Thus, EPCR is able to accommodate lysoPCh within its hydrophobic groove. Finally, the binding, according to the K D , was stronger than that observed with PCh and, of note, remarkably impaired the affinity of EPCR for APC and FVIIa (Online Supplemental Discussion). These findings fully conform to the "in silico" simulation. 21 PAF is a bioactive lipid structurally similar to lysoPCh, also generated by endothelial cells, and was able to displace PCh and bind to EPCR as well.
To find out whether lysoPCh and PAF influenced EPCR function in a more physiological condition, we moved to the cellular context. Unlike what happened in the experiments performed with sEPCR, there was no change in the EPCR-dependent APC binding when lysoPCh or PAF were directly added to endothelial cells. This result initially suggested that lipid substitution does not take place when EPCR is on the cell membrane. However, in an attempt to be closer to the in vivo condition, we studied whether the EPCR ability to bind to APC was modified upon manipulation of sPLA 2 -V, an endothelially expressed enzyme which is the main source of lysoPCh and PAF in that tissue: 24 sPLA 2 -V belongs to the superfamily of PLA2 enzymes 25 and, being constitutively expressed by endothelial cells, it is upregulated by inflammatory stimuli like TNF-α, VEGF or in inflammatory conditions such as atherosclerosis. Firstly, we incubated endothelial cells with the PLA2 inhibitor manoalide prior to assess APC binding. Unlike what happened when lysoPCh was directly given to cells, manoalide did increase the EPCR-dependent binding of APC, and this had to be due to the inhibition of sPLA 2 -V: although manoalide also inhibits sPLA 2 -IIa and X, the former is not present in resting endothelial cells [18] [19] [20] and the latter is not present either, as we showed (Online Figure II) . Accordingly, APC binding was notably reduced when endothelial cells were supplemented with sPLA 2 -V. Since SPR experiments made us discard a direct interaction between EPCR and sPLA 2 -V, the most likely explanation for these results is that sPLA 2 -V generates lysoPCh and PAF in the vicinity of EPCR, and the lipids so generated displace PCh from EPCR, which in turn partially loses its binding capacity. The fact that a similar mechanism has recently been demonstrated for the highly homologous CD1d reinforces our hypothesis. 17 As anticipated, the changes in the functionality of EPCR through sPLA 2 -V had relevant biological consequences i.e. the activation of protein C by thrombin and the antiapoptotic effect of APC were impaired as the sPLA 2 -V activity was increased and viceversa. Thus, a new role for sPLA 2 -V as a downregulator of EPCR function can be proposed, which would be specially important in scenarios of inflammation, in which its endothelial expression is enhanced. Since APC is one of the cornerstones of the crosstalk between inflammation and coagulation, it is interesting that we detected sPLA 2 -V in the endothelium in situations of injury leading to thrombosis, i.e. murine carotid artery, while it was not detected in noninjured vessels. Furthermore, not only was sPLA 2 -V detected on the endothelium but also inside the thrombus and on the trapped neutrophils, which suggests that sPLA 2 -V activity was increased upon insult, and in turn the locally generated lysoPCh and PAF diminished the protein C/APC binding ability of EPCR thus exacerbating the coagulative and inflammatory responses in the vicinity of the injured area, thereby facilitating thrombus formation. This theory is further substantiated by previous literature supporting a role for thrombin as a trigger of the release of lysoPCh by endothelial cells which could be mediated by an increase in sPLA 2 -V expression. 26 Furthermore, detection of sPLA 2 -V in neutrophils and release upon cell activation have also been previously reported. 27 Finally, the presence of sPLA 2 -V in the left atrial wall, with an attached thrombus, of a patient with atrial fibrillation, suggests that our observations can be applied to humans.
Our findings can be clinically relevant. Overexpression of sPLA 2 -V would not only reduce the amount of APC generated but would also impair the APC-dependent cell signaling through the EPCR-PAR-1 axis, thus reducing the APC-associated benefit in a variety of settings as endothelial barrier protection, apoptosis reduction, metastasis prevention and others. Also, circulating factor VII levels could become higher since a role for EPCR as a scavenger for factor VII, that would be cleared from the circulation, has been demonstrated. 28 Moreover, since we demonstrated that EPCR decreases the activation of FVII by factor Xa, 5 when sPLA 2 -V was overexpressed, FVIIa generation would be increased thus reinforcing the procoagulant properties that our results confer to sPLA2-V.
In summary, we have demonstrated that the major lipid bound to the hydrophobic groove of EPCR is PCh. PCh can be replaced by sPLA 2 -V-produced lysoPCh or PAF. As a consequence, the affinity of EPCR for protein C/APC and factor VII/VIIa decreases, which leads to a reduction in the endothelial capacity to generate APC and in the APC-evoked cell protective mechanisms. A new prothrombotic/proinflammatory role can be attributed to 
